GLP1R and diabetic kidney disease: This study is one of the first to systematically evaluate changes in soluble CD36 (sCD36) levels in response to GLP-1 receptor agonist (GLP-1RA) therapy based on real-world clinical data from patients with early-stage diabetic kidney disease (DKD).